## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.26 indicates fundamental undervaluation. Quality metrics strong (ROE 18%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($320.82)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. UnitedHealth stock rises today as 2026 opens; UNH holds gains after hours with earnings ahead**
- Source: ts2.tech | 20260102T230831 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth Group Incorporated shares rose on the first trading day of 2026, closing up 1.9% and gaining slightly after hours, with other managed-care peers also performing well. Investors are now focused on the company's upcoming January 27 earnings report for full-year 2025 results and 2026 guidance, particularly regarding medical costs, Medicare Advantage, and updates on operational reviews including diagnosis codes and the OptumRx unit. The stock's ability to hold above $330 and challenge the $340 area will be closely watched by traders.

**2. Chemistry Wealth Management LLC Raises Holdings in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20260101T101648 | Bullish | Relevance: 100%
- Chemistry Wealth Management LLC increased its stake in UnitedHealth Group (NYSE:UNH) by 59.2% in Q3, now owning 16,199 shares valued at $5.593 million, making it their 18th largest holding. Institutional investors collectively own 87.86% of UNH, with significant new investments from Norges Bank and Berkshire Hathaway. Analyst sentiment is generally positive, with a consensus "Hold" rating and an average price target of $385.54.

**3. UnitedHealth stock slips into year-end close â€” what traders are watching next**
- Source: ts2.tech | 20251231T220927 | Somewhat-Bearish | Relevance: 100%
- UnitedHealth Group Inc. stock slipped as the year closed, influenced by Minnesota's new Medicaid claim prepayment review process through Optum and broader health-care sector declines. Investors are now keenly awaiting UnitedHealth's full-year 2025 results and 2026 outlook, due on January 27, to assess medical-cost trends and regulatory scrutiny impact. The company's diversified operations make it sensitive to policy shifts, prompting focus on its medical care ratio and government health program headlines.

**4. UnitedHealth stock dips today as BlackCat ransomware guilty pleas revive cyber overhang**
- Source: ts2.tech | 20251231T180823 | Somewhat-Bearish | Relevance: 100%
- UnitedHealth Group shares fell on Wednesday after two cybersecurity professionals pleaded guilty to extorting American targets while working with the ALPHV "BlackCat" ransomware gang, which attacked UnitedHealth last year. Investors are closely watching UnitedHealth's ability to manage costs and regulatory issues as it heads into 2026, especially concerning its medical care ratio and compliance-related expenses. The company is set to release its full-year 2025 financial results and 2026 guidance on January 27, which will be a key catalyst for the stock.

**5. Why UnitedHealth Group (UNH) Outpaced the Stock Market Today**
- Source: Yahoo Finance | 20260102T231059 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) shares rose by 1.91% recently, outperforming the S&P 500, Dow, and Nasdaq. Despite previous declines, the company is expected to announce earnings on January 27, 2026, with anticipated EPS of $2.09 and revenue of $113.64 billion, driven by positive analyst revisions. UNH currently holds a Zacks Rank of #3 (Hold) and is trading at a premium compared to its industry average.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 15 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 18.9x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $304.7B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 18.9 |
| Current P/E | 20.6 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.3% to 2.3% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.7pp (needs >4.0% for momentum thesis). MRS_5 at 2.0% confirms short-term momentum alignment. Below SMA200 (0.96x), long-term trend not supportive. MACD histogram positive (0.61), confirming momentum. RSI neutral at 56. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.30% (CS: 73) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | 0.61 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 0.965x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $336.40
- **Stop Loss:** $320.82 (4.6% risk)
- **Target:** $367.56 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 92
- **Position Value:** $30,948.80
- **Portfolio %:** 30.95%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*